The global gene delivery technologies market size was valued at USD 5,119 million in 2024 and is expected to hit around USD 15,203 million by 2034 with a CAGR of 11.5% from 2025 to 2034.
| Market Size value in 2025 | USD 5,708 Million |
| Revenue Forecast in 2034 | USD 15,203 Million |
| Growth Rate | CAGR of 11.5% from 2025 to 2034 |
| Segments Covered: | Mode, application, method, region |
| Key Companies | Thermo Fisher Scientific Inc.; QIAGEN; Horizon Discovery Ltd.; OriGene Technologies, Inc.; Oxford Biomedica PLC; SignaGen Laboratories; Flash Therapeutics; Takara Bio Inc; Bio-Rad Laboratories, Inc.; System Biosciences, LLC.; Promega Corporation.; F. Hoffmann-La Roche Ltd; SIRION BIOTECH GmbH; Catalent, Inc. |
The gene delivery technologies market refers to the production, distribution, and application of gene delivery technology, which is required to condense DNA, transport the gene into the cell, and facilitate its release, thereby leading to gene expression. Gene delivery is a process of transfer of nucleic acids (NAs) such as complementary DNA (cDNA) or DNA, RNA interference (RNAi), and aptamers into the cells. Two main approaches emerged: in-vivo and ex-vivo modification. Gene delivery is a necessary step in gene therapy for the introduction or silencing of a gene to promote a therapeutic outcome in patients and has applications in the genetic modification of crops. There are several different methods of gene delivery for many types of cells and tissues. The goal of the research for the gene delivery system is to develop clinically relevant vectors like viral and non-viral vectors that are used to combat elusive diseases like Alzheimer’s, cancer, AIDs, etc. Gene technologies have many uses in areas like producing enzymes to use in food processing, for animal health to produce animal medicines and vaccines, and in agriculture to introduce pest or disease resistance, enhance drought tolerance, or enhance the nutritional value of a crop.
Technological advancement in gene delivery technologies is driving the growth of the gene delivery technologies market. Gene delivery systems are essentially necessary for the gene therapy of human genetic diseases. Accurate targeting through genome editing has emerged as a promising alternative to traditional therapeutic approaches. The most common and preferred physical gene delivery methods are biolistic particle delivery, which is also called gene gun delivery or particle bombardment, and electroporation, which is the use of electric field pulses to create pores in cell membranes. Chemical delivery methods use polymers and cationic lipids as transfer agents. The three genome targeting technologies, zinc finger nucleases, TALE nucleases, and CRISPR-Cas9, have facilitated a genome editing revolution. Lipid nanoparticles are allowing a new generation of engineered cell therapies with a push towards more complex cell engineering and gene editing for allogeneic therapies. Gene therapies are used to prevent, treat, or cure specific inherited disorders like sickle cell disease, beta thalassemia, hemophilia, alpha-1 antitrypsin deficiency, and cystic fibrosis. They also may be used to treat cancers or infections, including HIV. Gene therapy has been used to treat a smaller number of diseases, including an eye disorder called Leber congenital amaurosis and a muscle disorder called spinal muscular atrophy. Many more gene therapies are undergoing research to make sure that they will be effective and safe.
Increased investment in research and development drives the growth of the gene delivery technologies market. Investing in research and development (R&D) is a direct contributor to overall global success for many reasons. Research and development (R&D) drives innovation, improves competitive advantage, facilitates market expansion, and contributes to sustainable development. Additional or improved capital goods increase labor productivity by making companies more effective. Newer equipment or factories lead to more products being produced at a faster rate. This increased efficiency leads to economic growth for the country and a higher nationwide GDP. R&D can lead to innovations, maybe in terms of new products and services, enhanced processes, and new ways to interact with customers. These innovations can result in lower costs and greater profits.
According to a report published by cell trials data in April 2021,
Published by Kesiya Chacko
Related Reports
